Prevention of NMDA receptor sensitization by neurotoxic β-amyloid through polyphosphate coacervation

Werner E G Müller1, Sanja Perovic-Ottstadt1, Rita Dobmeyer2

  • 1ERC Advanced Investigator Grant Research Group at the Institute for Physiological Chemistry, University Medical Center of the Johannes Gutenberg University, Mainz 55128, Germany.

Insights

Inorganic polyphosphate (polyP) protects against Alzheimer's disease by chelating calcium, preventing amyloid-beta-induced neuronal death and N-methyl-d-aspartate receptor dysfunction.

Area of Science:

  • Neuroscience
  • Biochemistry
  • Pharmacology

Background:

  • Alzheimer's disease (AD) involves amyloid-beta (Aβ)-induced synaptic issues and calcium imbalance via N-methyl-d-aspartate (NMDA) receptors.
  • Inorganic polyphosphate (polyP), released from activated platelets, shows potential in preserving neuronal survival.

Purpose of the Study:

  • To investigate the neuroprotective effects of polyP against Aβ toxicity.
  • To elucidate the mechanisms underlying polyP's action, focusing on calcium regulation and NMDA receptor function.

Main Methods:

  • Primary rat neurons and PC12 cells were exposed to Aβ(25-35) and treated with sodium polyphosphate (Na-polyP).
  • Assessed neuronal apoptosis, NMDA receptor-mediated calcium influx, and polyP-serotonin coacervate formation.
  • Characterized release kinetics of polyP-based brain-targeted formulations.

Main Results:

  • Aβ(25-35) induced significant neuronal apoptosis within 3 days.
  • Na-polyP (50 µg/mL) completely prevented Aβ-induced neurotoxicity and reduced calcium influx.
  • Na-polyP formed calcium-chelating coacervates with serotonin, mitigating Aβ-induced NMDA receptor sensitization.

Conclusions:

  • Calcium chelation by polyP coacervates is a key mechanism protecting against Aβ neurotoxicity.
  • PolyP-based formulations offer a promising, mechanistically supported therapeutic strategy for Alzheimer's disease.

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Amyloid Fibrils03:03

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining, normally used to...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Desensitization and Tachyphylaxis01:20

Desensitization and Tachyphylaxis

Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
Several...